Johnson Pharmacare Limited announced its unaudited standalone financial results for the quarter ended 31st December, 2025, during a board meeting held on 14th February, 2026. The pharmaceutical company continues to face operational challenges with no revenue generation and mounting losses.

Financial Performance Overview

The company's financial performance for Q3 FY26 shows continued losses across all operational metrics. Johnson Pharmacare reported zero revenue from operations for the current quarter, consistent with previous quarters.

Expense Analysis

The company's expense structure for Q3 FY26 reveals significant increases across multiple categories compared to the previous quarter.

Finance costs emerged as the largest expense component at 4.01 lakhs for the current quarter, while other expenses contributed 2.18 lakhs. Employee benefits expense decreased to 0.21 lakhs from 0.30 lakhs in the previous quarter.

Nine-Month Performance

For the nine months ended 31st December, 2025, Johnson Pharmacare recorded a cumulative loss of 12.34 lakhs compared to 7.06 lakhs in the corresponding period of the previous year. Total expenses for the nine-month period stood at 12.34 lakhs, with other expenses accounting for 7.25 lakhs, finance costs at 4.28 lakhs, and employee benefits at 0.81 lakhs.

Share Capital and Earnings Per Share

The company maintains a paid-up equity share capital of 5,500.00 lakhs with a face value of Re. 1 per share. Basic and diluted earnings per share for continuing operations stood at (0.00) for Q3 FY26, Q2 FY26, and Q3 FY25.

Regulatory Compliance

The board also addressed compliance with Regulation 32 of SEBI (LODR) Regulations, 2015, confirming its non-applicability as the company has not issued shares through rights issue, preferential allotment, or any other issue during the quarter ended 31st December, 2025. The results were approved during a board meeting held at the company's registered office in Ahmedabad, Gujarat, under the chairmanship of Additional Director Rajender Parsad.

Johnson Pharmacare Limited announced the appointment of Ms. Parul Agrawal as Additional Non-Executive & Independent Director following a board meeting held on February 13, 2026. The appointment was approved in compliance with regulatory requirements and takes effect immediately.

Board Meeting Details

The board meeting was conducted on Friday, February 13, 2026, from 12:15 p.m. to 12:45 p.m. The primary agenda item was the appointment of the new director pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Profile and Qualifications

Ms. Parul Agrawal brings her educational background and professional experience to the board. Her appointment strengthens the company's independent director composition as required under corporate governance norms.

Regulatory Compliance

As part of the appointment process, Ms. Agrawal has submitted the required non-debarment declaration pursuant to SEBI Circular No. LIST/COMP/14/2018-19 dated June 20, 2018. In her declaration, she confirmed that she is not debarred from accessing the capital market and that neither SEBI nor any other authority has passed any order against her that would prevent her from holding the office of director.

The appointment demonstrates Johnson Pharmacare Limited's commitment to maintaining robust corporate governance standards and compliance with regulatory requirements. The company is registered in Gujarat with its office located in Ahmedabad, and the new director's appointment was signed off by Additional Director Umesh Kumar (DIN: 07015921) on behalf of the board.